Here's a CBAI evaluation done by a shareholder I just ran across..
something to bat around..
I'm back in CBAI with a few million shares. I like that Red Oak took over just when CCEL was trying to move in. Clearly IMO the share price should be higher. I think around .02 right now. I did some math based on this last 10Q and resulting PR. Joe said recurring revenue was $660K in 2Q. I believe today the annual storage fee is $125 but at one time may have been as low as $90. Not totally sure about that though. So if we take an average of $110 storage charge and relate that to the $660K times 4 to annualize the recurring revenue you get $2.640M. Now if you divide that by $110 that says to me CBAI has about 24,000 samples. Anyone see anything wrong with that assumption? It was closer to 30,000 including the Subs.
Now lets look at Cap Value. Today there are 1,271,052,632 shares outstanding. That times .0036 says the current Cap Value is $4.6M. Now lets look at the Cord Blood Registry valuation. They got $700M for 600K samples or $1166 per. That's high but I don't think $1000 per is too high. So 24,000 CBAI samples times $1000 equals $24M. $24M divided by the shares equals $ .019 PPS vs todays .0035.
Does anyone have a clue how many samples CCEL has? I believe it's over 60,000 but lets use that number for now. $1000 times 60,000 equals $60M Cap Value. With 9,665,734 Outstanding Shares today divided by my assumed 60,000 samples you get a share price of $6.20. It appears to me CCEL is still trading as a Pink Sheet. At least per Fidelity. The reason is they don't have enough trading shares outstanding. Lots of insders holding shares. That hurts the share value and is to me part of the reason the share price is so understated.
No longer is CBAI controlled by an enemy of CCEL. Remember Matt worked for CCEL as a Consultant at one time then went off and started a competing company. A merger would bring both valuations up to date immediatly plus the combined Company would immediately be more profitable
